Health-associated quality of life impairment in people who inject drugs (PWID) after bloodstream infection

Abstract

Background

People who inject drugs (PWID) have high rates of bloodstream infections (BSI) with Staphylococcus aureus (SA) and group A streptococcus (GAS). Little is known about health-related quality of life outcomes after BSI.

Methods

We performed a prospective pilot cohort study of patients with BSI due to SA or GAS. Health-related quality of life, anxiety, depression and cognitive function were assessed using validated tools (EQ5-5D-5L), Hospital Anxiety and Depression Score (HADS) and Montreal Cognitive Assessment (MOCA) at baseline, 28 days post-discharge and 6 months post-infection.

Findings

66 patients were recruited over a 12-month period, including 17 PWID. For the whole cohort, global health rank improved from baseline to day 28 (median 40 to 60, p=0.002), with no significant improvement from day 28 to day 168 (median 60 to 75, p=0.161). At baseline, PWID had lower overall health-related quality of life than non-PWID (median 25 vs 45, p=0.229), persisting at day 28 (non-PWID median 65, PWID median 43, p=0.036) and day 168 (non-PWID median 75, PWID median 40, p=0.035). This difference was driven by worse scores in the EQ-5D-5L mental health component and HADS, with HADS scores being significantly impaired in PWID at baseline (p=0.001) and day 28 (p=0.007).

Conclusion

PWID have impaired health-related quality of life after SA and GAS BSI that persists for up to 6 months. Poor mental health is the major component of this, and further studies could clarify if this is a target for intervention.